• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 3
  3. Author

Online ISSN: 2515-8260

Volume9, Issue3

Comparison of Silodosin and Dapoxetine in “on-demand” treatment of Premature ejaculation:A randomized controlled study

    Dr. Shiv Shankar Sharma,Dr. Shivam Priyadarshi, Dr. Nachiket Vyas, Dr.S. S. Yadav, Dr. Govind Sharma

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 3, Pages 2819-2823

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Aim: To compare Silodosin and Dapoxetine in the “on-demand” treatment of premature ejaculation.
Material and method: The study was conducted in the department of urology and renal transplant S.M.S. Medical College Jaipur from 1st January 2018 to 31st December 2018. We enrolled 90 self-reported casesof PME and excluded the patients below 18 years and above 50 years; patients suffering from orthostatic hypotension, renal impairment, and hepatic impairment. All patients were divided equally into three groups by a simple randomization method using computer-generated random numbers i.e.,Group A(Silodosin 4 mg on-demand), Group B (Dapoxetine 30 mg on-demand), and Group C (placebo on demand). Intravaginal ejaculatory latency time (IELT), premature ejaculation profile (PEP), and the clinical global impression of change for premature ejaculation (CGIC) were recorded in patients, before the initiation of the treatment and after ten coital activities or after one month. Any adverse effects reported by the patients were also recorded.
Results: There was a significant improvement in intravaginal ejaculation latency time in both Silodosin and Dapoxetine groups. Patients of group A and group B reported better scores in all aspects of premature ejaculation profile as compared to placebo. Only three patients reported a reduced amount of ejaculate with silodosin but it was not bothersome to patients.
Conclusion: Silodosin 4 mg may be used safely as a treatment option for PME as its safety profile in LUTS is already well established. It is as effective as Dapoxetine 30 mg with a better side effect profile in the management of premature ejaculation.
Keywords:
    Premature Ejaculation Silodosin Dapoxetine IELT
  • PDF (350 K)
  • XML
(2022). Comparison of Silodosin and Dapoxetine in “on-demand” treatment of Premature ejaculation:A randomized controlled study. European Journal of Molecular & Clinical Medicine, 9(3), 2819-2823.
Dr. Shiv Shankar Sharma,Dr. Shivam Priyadarshi, Dr. Nachiket Vyas, Dr.S. S. Yadav, Dr. Govind Sharma. "Comparison of Silodosin and Dapoxetine in “on-demand” treatment of Premature ejaculation:A randomized controlled study". European Journal of Molecular & Clinical Medicine, 9, 3, 2022, 2819-2823.
(2022). 'Comparison of Silodosin and Dapoxetine in “on-demand” treatment of Premature ejaculation:A randomized controlled study', European Journal of Molecular & Clinical Medicine, 9(3), pp. 2819-2823.
Comparison of Silodosin and Dapoxetine in “on-demand” treatment of Premature ejaculation:A randomized controlled study. European Journal of Molecular & Clinical Medicine, 2022; 9(3): 2819-2823.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 241
  • PDF Download: 421
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus